Glaxo executive opposes splitting FDA reviews, but editorial in favor

GlaxoSmithKline's R&D chairman opposes creation of a separate agency to monitor the safety of FDA-approved drugs. Tachi Yamada said splitting the process is a hazardous idea and drugs should be reviewed in their totality. Separately, a Journal and Constitution editorial supports the proposal to create an agency independent of the FDA because the agency no longer has the trust of the public.

View Full Article in:

Reuters · Journal and Constitution (Atlanta) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN